Related Experiment Video
Updated: Nov 18, 2025

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and
HoUng Kim1,2, Rieke Alten3, Fraser Cummings4
1Celltrion Healthcare , Incheon, Republic of Korea.
Abstract:
The biosimilar concept is now well established. Clinical data accumulated pre- and post-approval have supported biosimilar uptake, in turn stimulating competition in the biologics market and increasing patient access to biologics. Following technological advances, other innovative biologics, such as "biobetters" or "value-added medicines," are now reaching the market. These innovative biologics differ from the reference product by offering additional clinical or non-clinical benefits. We discuss these innovative biologics with reference to CT-P13, initially available as an intravenous (IV) biosimilar of reference infliximab. A subcutaneous (SC) formulation, CT-P13 SC, has now been developed. Relative to CT-P13 IV, CT-P13 SC offers clinical benefits in terms of pharmacokinetics, with comparable efficacy, safety, and immunogenicity, as well as increased convenience for patients and reduced demands on healthcare system resources. As was once the case for biosimilars, nomenclature and regulatory pathways for innovative biologics require clarification to support their uptake and ultimately benefit patients.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Microorganisms in Medicine and Therapeutics

